Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Brisebois is a 3-star analyst with an average return of 2.4% and a 40.11% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Savara, Praxis Precision Medicines, and Opus Genetics.
Currently, the analyst consensus on Ovid Therapeutics is a Strong Buy with an average price target of $5.33.
Based on Ovid Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $16.99 million. In comparison, last year the company earned a revenue of $130 thousand and had a GAAP net loss of $10.24 million
